SYNERGY: Anti-LINGO Agent Misses Primary Endpoint in MS SYNERGY: Anti-LINGO Agent Misses Primary Endpoint in MS

Opicinumab, a novel remyelinating agent, didn ' t show a ' linear dose response ' of clinical improvement across 4 treatment groups. But it may still have potential for certain patients, say experts.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news